CandlesenseCandlesense
LLY•benzinga•

Eli Lilly's Weekly Insulin Dose On Par With Commonly Used Daily Doses, Phase 3 Studies Show

Summary

Eli Lilly phase 3 trials reveal once-weekly insulin efsitora as a non-inferior alternative to daily basal insulins for type 2 diabetes.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on May 16, 2024 by benzinga

← Back to LLY News
    Eli Lilly's Weekly Insulin Dose On Par With Commonly Used Daily Doses, Phase 3 Studies Show | LLY Stock News | Candlesense